Vous avez cherché: frigivelsessyndrom (Danois - Anglais)

ved alvorlige reaktioner se venligst cytokin frigivelsessyndrom ovenfor.
please see cytokine release syndrome above for severe reactions.

patienter skal nøje monitoreres for cytokin frigivelsessyndrom (se pkt.4. 4) .
patients should be closely monitored for the onset of cytokine release syndrome (see section 4.4) .

* tumor lyse syndrom * cytokin frigivelsessyndrom serumsyge hepatitis b-reaktivering5
*tumour lysis syndrome *cytokine release syndrome serum sickness hepatitis b reactivation5

kliniske fund ved anafylaksi kan ligne de kliniske fund på cytokin frigivelsessyndrom (beskrevet ovenfor).
clinical manifestations of anaphylaxis may appear similar to clinical manifestations of the cytokine release syndrome (described above).

yderligere behandling af patienter efter fuldstændig ophør af kliniske fund og symptomer har sjældent resulteret i gentagelse af alvorligt cytokin frigivelsessyndrom.
further treatment of patients after complete resolution of signs and symptoms has rarely resulted in repeated severe cytokine release syndrome.

alvorligt cytokin frigivelsessyndrom er karakteriseret ved alvorlig dyspnø ofte sammen med bronchospasme og hypoxi, foruden feber, kulderystelser, rigor, urticaria og angioødem.
severe cytokine release syndrome is characterised by severe dyspnea, often accompanied by bronchospasm and hypoxia, in addition to fever, chills, rigors, urticaria, and angioedema.

patienter som udvikler svært cytokin frigivelsessyndrom bør have deres infusion afbrudt omgående (se pkt.4. 2) og modtage kraftig symptomatisk behandling.
patients who develop severe cytokine release syndrome should have their infusion interrupted immediately (see section 4.2) and should receive aggressive symptomatic treatment.

hvis patienten får en svær reaktion relateret til infusionen, anafylaksi, en svær allergisk reaktion eller cytokin-frigivelsessyndrom relateret til infusionen, skal yderligere administration af sylvant seponeres.
if the patient develops a severe infusion related reaction, anaphylaxis, severe allergic reaction, or cytokine release syndrome related to the infusion, further administration of sylvant should be discontinued.

infusionsrelaterede bivirkninger herunder cytokin frigivelsessyndrom (se pkt.4. 8) ledsaget af hypotension og bronchospasme er set hos 10% af patienter behandlet med mabthera.
infusion related adverse reactions including cytokine release syndrome (see section 4.8) accompanied by hypotension and bronchospasm have been observed in 10% of patients treated with mabthera.

exacerbationer af hjertelidelser som angina pectoris, kongestiv hjertesygdom eller svære hjertetilfælde (hjertestop, myokardieinfarkt og atrieflimren), lungeødem, multiorgansvigt, tumorlysesyndrom, cytokin frigivelsessyndrom, nyresvigt og respirationssvigt blev rapporteret med lavere eller ukendt hyppighed.
12 events (heart failure, myocardial infarction, atrial fibrillation), pulmonary oedema, multi-organ failure, tumour lysis syndrome, cytokine release syndrome, renal failure, and respiratory failure were reported at lower or unknown frequencies.